Navigation Links
Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
Date:5/15/2009

PHILADELPHIA, May 15 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (CII) and investigational non-scheduled guanfacine extended release, at a national scientific meeting of psychiatrists to be held May 16-21 in San Francisco, CA.

"Shire is committed to the advancement of ADHD treatment research and eager to present results from a spectrum of studies," said Jeffrey Jonas, MD, Senior Vice President of Research & Development for the Specialty Pharmaceuticals business at Shire. "We believe the lisdexamfetamine dimesylate and guanfacine extended release study findings to be presented will contribute greatly to the growing body of research and development for physicians in the field of ADHD."

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate

May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDT

Pharmacokinetics of Intranasal Versus Oral Administration of Lisdexamfetamine Dimesylate in Healthy Adults

Poster Presentation #NR2-027

May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDT

Duration of Effects of Lisdexamfetamine Dimesylate on Behavior of Children With Attention-Deficit/Hyperactivity Disorder in Naturalistic Settings

Poster Presentation # NR2-029

May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDT

Patient Experience and Satisfaction with Lisdex
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
2. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
3. Families Invited to Celebrate Shire Day at Boston Childrens Museum
4. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
5. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
6. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
7. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
8. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
9. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
10. Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
11. Anthem Blue Cross and Blue Shield in New Hampshire Announces Unique Enhancement to its ePrescribing Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Whatever one's feelings about the Fifty Shades of ... Everyone from hard-core fans of the trilogy, to people in ... hasn't read even one of the books, is putting their ... the general manager of HUSH, a leading retailer of adult ... very good thing. , "When the books came out in ...
(Date:3/4/2015)... The defibrillators report provides insights into the growth ... the global market is expected to grow at a ... by 2019. It expects the emerging markets to provide ... established players in the market. , According to the ... at the highest CAGR during the next five years. ...
(Date:3/4/2015)... TheraBreath is proud to announce a new probiotic lozenge ... with overall health. , Many health experts agree that ... bad bacteria that can cause unwanted infections. While most people ... will need the help of a probiotic to elevate the ... Packed with the S. salivarius M18 & K12 strains of ...
(Date:3/4/2015)... 2015 Follow us on ... growth worldwide, supported by the numerous intraoperative, and ... and single incision surgery will continue to spur ... invasive surgery, driving its adoption among patients and ... site, lower blood loss, shorter hospital stays, faster ...
(Date:3/4/2015)... 2015 Durrie Vision, a ... first in the region to offer two new intraocular ... cataracts. The implantable Tecnis® Multifocal lenses – now offered ... at a range of distances. Earlier this year the ... of two new IOLs – the Tecnis® Multifocal +2.75D ...
Breaking Medicine News(10 mins):Health News:Fifty Shades of Grey™ Has Canadians Talking About Sex. 2Health News:Defibrillators Market worth $12.9 Billion by 2019 with Rise in Aging Population - New Research Report by MarketsandMarkets 2Health News:Defibrillators Market worth $12.9 Billion by 2019 with Rise in Aging Population - New Research Report by MarketsandMarkets 3Health News:TheraBreath introduces a new line of probiotic lozenges that strengthen the body’s ability to fight germs 2Health News:Growing Demand for Less Invasive Procedures Drives Growth in the Endoscopy Systems Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Demand for Less Invasive Procedures Drives Growth in the Endoscopy Systems Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Growing Demand for Less Invasive Procedures Drives Growth in the Endoscopy Systems Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Durrie Vision First in Region to Offer New Tecnis® Multifocus Lenses 2
... than half of Americans know two particular fats boost ... Fewer than half of Americans realize there are two ... a new survey shows. , So, while many have ... fats and saturated fats, the American Heart Association (AHA) ...
... specific pieces of non-coding genetic material known as microRNAs ... cancer to other parts of the body. Researchers at ... Ohio State University Medical Center in Columbus have identified ... The findings, reported at the annual meeting of the ...
... ... Center, ... planning and interiors,firm, has transformed a shuttered South of Market warehouse ... As the new "front door" for the downtown university, the,former Swallow ...
... Indiana experienced a 50 percent membership ... growth since 2007, ... this 14-year-old, not-for-profit,Indiana managed health care plan -- surpassing the 300,000 mark ... 2007, the,company has also grown its employee base by 182 percent -- ...
... CHAPEL HILL, N.C., May 30 Creating an ... of a new product,s introduction.,A product,s promotion relies ... it.,Top benchmark companies ensure that they create effective, ... of a new product., The detailed report ...
... 30 Members of District,1199C of the National ... morning (Friday) ratified a four-year contract agreement with,Hahnemann ... increase in,wages and benefits., District 1199C represents ... reached with the hospital following some 16 and ...
Cached Medicine News:Health News:Some Fats Deserve Change of Heart 2Health News:Jefferson, Ohio State team find gene signature profile for metastasis 2Health News:Golden Gate University Opens New Student Services Center 2Health News:MDwise Enrollment Exceeds 300,000 Members 2Health News:Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence 2
(Date:3/3/2015)... March 3, 2015  Cumberland Pharmaceuticals Inc. (NASDAQ: ... on hospital acute care and gastroenterology, today announced ... Company,s revenue grew 15% in 2014 to $37 ... or $0.35 per diluted share. At the end ... $95 million including $55 million in cash and ...
(Date:3/3/2015)... , March 3, 2015  This industry report package offers the most ... for safety glass in the world and in the top 10 global ... country reports from the following countries: Australia ... Germany , Italy , Japan ... United Kingdom , United States ...
(Date:3/3/2015)... , March 3, 2015  BioPharmX Corporation (OTCQB: BPMX), ... novel drug delivery products to address unmet needs in ... Jim Pekarsky , chief executive officer and co-founder of ... Roth Capital Partners Conference on Wednesday, March 11 at ... Niguel in Dana Point ...
Breaking Medicine Technology:Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 2Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 3Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 4Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 5Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 6Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 7Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 8Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 9Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 10Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 11Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 12Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 13Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 14Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 15Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 16Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 17Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 18Global Safety Glass Market to 2019 - Market Size, Top 10 Countries, Trends, and Forecasts 2BioPharmX Corporation To Present At 27th Annual Roth Capital Partners Conference On March 11, 2015 2BioPharmX Corporation To Present At 27th Annual Roth Capital Partners Conference On March 11, 2015 3
... 2007 - Amgen,(NASDAQ: AMGN) today announced ... a,randomized, double-blind, placebo-controlled, multicenter Phase 3,study ... previously untreated,patients with extensive-stage small-cell lung ... demonstrated,no statistically significant difference in risk ...
... CAMBRIDGE, Mass., April 18, 2007 /PRNewswire-FirstCall/ --,Idenix Pharmaceuticals, ... development and commercialization of drugs for,the treatment of ... 11 abstracts have been accepted for,presentation at the ... in Washington D.C. from May 19 to 24. ...
Cached Medicine Technology:Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 2Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 3Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 4Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 5Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 6Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 7
Inquire...
Inquire...
Agarose I (Molecular Biology Grade) - A regular melting temperature agarose for electrophoresis requiring an exceptional level of purity with unequaled performance....
... Biology Grade, is used for ... acids. It can be used ... 0.2 to 40 kb., Each ... tested and certified to be ...
Medicine Products: